Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Morphosys Ag ADR
(NQ:
MOR
)
18.31
+0.01 (+0.05%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Morphosys Ag ADR
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
July 28, 2022
Via
ACCESSWIRE
MorphoSys AG: Invitation to MorphoSys' Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
July 28, 2022
Conference Call Alert
From
MorphoSys AG
Via
AccessWire
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / July 26, 2022 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary U.S. net product sales of Monjuvi® (tafasitamab-cxix) for the second quarter 2022...
From
MorphoSys AG
Via
AccessWire
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
Via
ACCESSWIRE
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
Via
ACCESSWIRE
MorphoSys Stock Skyrockets On Entering Equity Participation and License Agreements With HIBio
June 14, 2022
Via
Benzinga
MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland
March 23, 2022
The
Via
Benzinga
MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
July 26, 2022
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
From
MorphoSys AG
Via
AccessWire
21 Stocks Moving in Wednesday's Pre-Market Session
June 22, 2022
Gainers Codex DNA, Inc. (NASDAQ: DNAY) rose 64.5% to $3.52 in pre-market trading after declining 10% on Tuesday.
Via
Benzinga
Week In Review: Joincare Plans $300-$400 Million IPO On Swiss Exchange
June 18, 2022
Joincare Pharmaceutical of Shenzhen plans to list on the SIX Swiss stock exchange, an unusual venue for a China biopharma. The company said it aims to broaden its financing sources and increase global...
Via
Talk Markets
The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data
June 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
55 Stocks Moving In Wednesday's Mid-Day Session
June 15, 2022
Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares surged 92.4% to $2.77 after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity...
Via
Benzinga
24 Stocks Moving in Wednesday's Pre-Market Session
June 15, 2022
Gainers Boxed, Inc. (NYSE: BOXD) rose 38.3% to $1.95 in pre-market trading. Boxed reported that Director Andrew Pearson bought 150,000 shares at an average price of $1.82 per share.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
June 14, 2022
Gainers
Via
Benzinga
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
June 14, 2022
From
MorphoSys AG
Via
Business Wire
The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate
June 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
June 13, 2022
Gainers
Via
Benzinga
MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
June 10, 2022
From
MorphoSys
Via
Business Wire
MorphoSys AG Reports Outcome of Annual General Meeting 2022
May 18, 2022
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 18, 2022 / MorphoSys AG (FSE:MOR); (NASDAQ:MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and...
From
MorphoSys AG
Via
AccessWire
MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
May 12, 2022
From
MorphoSys
Via
Business Wire
MorphoSys AG Reports First Quarter 2022 Financial Results
May 04, 2022
From
MorphoSys AG
Via
Business Wire
Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
April 28, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
MorphoSys AG
Via
AccessWire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
March 24, 2022
Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV) shares moved upwards by 55.5% to $2.13 during Thursday's pre-market session. The market value of their outstanding...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale
March 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with r/r DLBCL
March 22, 2022
MorphoSys and Incyte Announce Swissmedic Temporary Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell...
From
MorphoSys AG
Via
AccessWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
March 22, 2022
Gainers Palisade Bio (NASDAQ:PALI) stock rose 59.0% to $1.28 during Tuesday's pre-market session. The company's market cap stands at $23.3 million. As per the news...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
March 22, 2022
Grab your cup of coffee, investor! We're starting off the day with a dive into the biggest pre-market stock movers for Tuesday!
Via
InvestorPlace
MorphoSys AG Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 16, 2022
From
MorphoSys AG
Via
Business Wire
Earnings Scheduled For March 16, 2022
March 16, 2022
Companies Reporting Before The Bell • Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million. • Tarena...
Via
Benzinga
National Comprehensive Cancer Network(R) Updates Designation of Monjuvi(R) (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas
March 15, 2022
BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN)...
From
MorphoSys AG
Via
AccessWire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.